Vimta Labs Reports ₹416 Crore FY26 Revenue, Launches Biologics Business

Annual revenue surged 19.5% to INR 4,163 million, with Q4 revenue climbing 16.6% to INR 1,120 million.

Q4 and Full-Year Results

Vimta Labs announced its Q4 FY26 results, reporting strong financial performance for the fiscal year. Total yearly income grew by 19.5% to INR 4,163 million (approx. ₹416 crore), driven by consistent demand in its core testing segments. For the fourth quarter, revenue increased by 16.6% year-on-year to INR 1,120 million. The company also reported a healthy EBITDA margin of 37.6% for Q4, contributing to an annual margin of 35.8%. The company remains debt-free and holds cash and equivalents of approximately INR 650 million, indicating strong financial health.

Why This Matters

This quarter marks Vimta Labs' strategic entry into the biologics contract research segment, a high-growth area within the pharmaceutical services industry. Management expressed confidence in achieving aggressive growth targets, aiming for a 20% to 25% CAGR. The company's new facilities are built to support growth for the next 4-5 years, suggesting a long-term expansion vision.

Strategic Foundation

In 2022, Vimta Labs expanded its international reach by acquiring VIMTA USA, boosting its presence in the North American market. Historically, the company has invested in expanding capacities for its pharmaceutical and food testing services to meet growing client demands. The strategic decision to enter the biologics contract research space was a key focus for FY26, building on its established expertise.

What Changes Now

Shareholders can expect the new biologics business to move into its execution phase, potentially unlocking new revenue streams. The company's existing capacity expansions are positioned to cater to medium-term growth objectives. A net debt-free status ensures financial flexibility for strategic initiatives and working capital needs. Investors will monitor margin performance against rising input costs and manpower expenses. The expanded US subsidiary is expected to drive better customer proximity and service delivery.

Risks to Watch

Geopolitical conflicts are impacting input and consumable costs, leading to higher operational expenses. Talent attrition remains an industry-wide challenge, which could affect operational efficiency and recruitment costs. Management stated that previous leadership issues in the electronics and electrical testing segments have been resolved.

Peer Comparison

Vimta Labs' FY26 revenue stood at INR 4,163 million with an EBITDA margin of 35.8%. Competitor Syngene International reported FY24 revenue of INR 3,895 million and an EBITDA margin of approximately 25%. Lambda Therapeutic Research posted FY24 revenue of INR 1,220 million and an EBITDA margin around 15%.

Key Metrics and Targets

Vimta Labs aims to reach revenue run rates equivalent to its earlier INR 500 crore target by Q4 FY26. Export revenue constituted 38% of total revenue in Q4 FY26, with utilization expected to pick up gradually over two years. Management anticipates a potential 1-2% margin reduction due to rising input and manpower costs, even as they aim for stable overall margins.

What to Track Next

Successful integration and market traction of the new biologics contract research business. The company's ability to maintain its target 20-25% CAGR growth. EBITDA margin performance amid ongoing geopolitical cost pressures and talent attrition. How cash reserves are deployed and future capital expenditure plans. Performance of the US subsidiary in improving customer engagement.